The market for insulin currently valued at around $3bn, with an annual growth of almost 10%, and sales of over $5 billion in 2004, makes it very attractive for business.
January 4, 2006 (Press Release) --
The market for insulin currently valued at around $3bn, with an annual growth of almost 10%, and sales of over $5 billion in 2004, makes it very attractive for business.
A major Indian pharma company on launching India's first recombinant Human insulin achieved the distinction of being the first Asian company to develop, manufacture and market the drug. Recombinant Human Insulin is devoid of the risks such as viral infections and neurological disorders, normally associated with insulin derived from animals.
The market research report "Insulin Delivery System-The State of the Science and Market Opportunities" published by RNCOS have experts arriving at the conclusion that the market share of recombinant human Insulin will rise from its present 10% to 60% during the next 4-5 years.
Human insulin has a very short shelf life and is extremely toxic if administered in large doses. Diabetic patients are required to inject themselves with insulin several times per day, which is very painful. Pharmaceutical companies have been encouraged to develop insulin with varying (prolonged, intermediate, short, mixed) durations of action. Alternatives to subcutaneous injection delivery are being explored, which may allow treatments tailor-made to suit the needs of the individual patient.
Besides India, there are only three pharma companies (one in US and other two in Europe) currently in the fray to control the global market for Recombinant Human Insulin.
To purchase your copy: http://www.rncos.com/Report/Biotech06.htm
For more information about the report please visit www.rncos.com
A major Indian pharma company on launching India's first recombinant Human insulin achieved the distinction of being the first Asian company to develop, manufacture and market the drug. Recombinant Human Insulin is devoid of the risks such as viral infections and neurological disorders, normally associated with insulin derived from animals.
The market research report "Insulin Delivery System-The State of the Science and Market Opportunities" published by RNCOS have experts arriving at the conclusion that the market share of recombinant human Insulin will rise from its present 10% to 60% during the next 4-5 years.
Human insulin has a very short shelf life and is extremely toxic if administered in large doses. Diabetic patients are required to inject themselves with insulin several times per day, which is very painful. Pharmaceutical companies have been encouraged to develop insulin with varying (prolonged, intermediate, short, mixed) durations of action. Alternatives to subcutaneous injection delivery are being explored, which may allow treatments tailor-made to suit the needs of the individual patient.
Besides India, there are only three pharma companies (one in US and other two in Europe) currently in the fray to control the global market for Recombinant Human Insulin.
To purchase your copy: http://www.rncos.com/Report/Biotech06.htm
For more information about the report please visit www.rncos.com
Email
Print
SPAM
LEAVE A COMMENT
